{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.58","upperLimit":"0.92","value":"0.75"},{"groupId":"OG001","lowerLimit":"0.61","upperLimit":"0.97","value":"0.79"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"Relapse free survival is defined as the time from study registration to recurrence after local therapy or death from any cause. Recurrence was counted only if it occurred after definitive local therapy (surgery and/or radiotherapy). Patients achieving durable complete responses to PCD without local therapy, and patients receiving local therapy without subsequent recurrence, were censored at last follow-up.","dispersionType":"95% Confidence Interval","groups":[{"description":"cis 75 mg/m2 (SOC), doce 74 mg/m2 (SOC), pembro 200mg (Exp), Q3W IV","id":"OG000","title":"Experimental (Cis/Doce/Pembro)"},{"description":"Out of the experimental group these subjects had pathological complete response","id":"OG001","title":"PCR Participants"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"from first study registration to recurrence after local therapy or death from any cause (up to 2 years follow up)","title":"To Determine the 2-year Relapse-free Survival (RFS) and Overall Survival (OS) in the Overall Population and in the Subgroup Who Achieves a pCR (RFS)","type":"SECONDARY","unitOfMeasure":"proportion of participants"}